[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spo2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spo2":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,68,80,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053461","philips-fast-spo2-technology-with-masimo-sensors-for-spo2-monitoring-in-the-neonatal-infant-and-pediatric-populations-100053461",false,"NCT07223177","Philips FAST SpO2 Technology With Masimo Sensors for SpO2 Monitoring in the Neonatal, Infant, and Pediatric Populations","Inclusion Criteria:\n\n* Subject falls within the indicated population for the Philips FAST SpO2 Monitor with the Masimo sensor.\n* Subject is less than 22 years of age (pediatric subject per US FDA definition).\n\nExclusion Criteria:\n\n* Subject has a skin condition or deformity at the planned sensor application site, which would preclude sensor placement and measurements as standard of care (e.g., psoriasis, eczema, angioma, scar tissue, burn, fungal infection, substantial skin breakdown).\n* Confounders of pulse oximetry per sensor direction for use (DFU).\n* Subject with distinct geographic variances in skin pigmentation (e.g., vitiligo), where the sensor is applied.\n* Subject has an absence or deformities of limbs or severe edema, which would interfere with sensor application or prevent the proper fit of the sensors.\n* Subject with nail polish or acrylic nails on the digits where sensor needs to be applied, who opts to not remove it.\n* Subject with known allergic reactions to adhesive tapes.\n* Subject is not suitable for the investigation at the discretion of the clinical research team.",true,"ALL","0 Years","21 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this study is to verify the form, fit and function of the Philips FAST technology with Masimo neonatal, infant and pediatric sensors for SpO2 monitoring in the respective indicated populations. The study design uses convenience sample data collection from neonatal, infant, and pediatric sensors within their respective indicated patient populations that have a range of different skin pigmentations, simultaneously with an FDA cleared pulse oximeter as a comparator.",[27],"SpO2","RECRUITING","2026-07-09",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2025-12-17",{"date":36,"type":21},"2026-12-31",{"name":38,"class":39},"Masimo Corporation","INDUSTRY",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100638570","spo2-infant-and-pediatric-study-100638570","NCT07615738","SpO2 Infant and Pediatric Study","Assessment of TruSignal SpO2 Form, Fit and Clinical Performance With Infant and Child Patients","SpO2 Peds","Inclusion Criteria:\n\n* subjects are 1-23 months (infant cohort) or 2-12 years old (child cohort)\n* requiring arterial blood samples per the site's standard of care.\n\nExclusion Criteria:\n\n* Fractional Methemoglobinemia (FMetHb \\>2%) or Fractional carboxyhemoglobinemia (FCOHb \\>3%), within 24 hours of arterial blood draw.\n* Severe anemia (tHb \\\u003C7g\u002FdL) within 4 hours prior to arterial blood gas draw.\n* Hematocrit (Hct) \\\u003C25 within 4 hours prior to arterial blood gas draw.\n* Patients with injuries, deformities, or abnormalities which may prevent proper application of the sensor.\n* Patients on Extracorporeal Membrane Oxygenation (ECMO).\n* Patients receiving point of care (POC) testing for blood gases.\n* Patients with diseases\u002Fconditions that may cause differential (or reverse differential) cyanosis including, but not limited to:\n* Patent ductus arteriosus with pulmonary arterial hypertension.\n* Pulmonary hypertension and left-heart abnormalities aortic arch hypoplasia, interrupted aortic arch, critical coarctation, and critical aortic stenosis.\n* Children with transposition of the great arteries (TGA) and coarctation of the aorta or interrupted aortic arch, and TGA with suprasystemic pulmonary vascular resistance.\n* At the discretion of the principal investigator or designee due to the subject health condition.","29 Days","12 Years",{"count":52,"type":21},180,[24],"This study evaluates the pulse oximetry (SpO₂) sensor for clinical performance, form, and fit in hospitalized infants and children (28 days to 12 years). It compares SpO₂ measurements from the device to arterial oxygen saturation (SaO₂) values from arterial CO-oximetry, and assesses the reliability of usable data, performance across skin tones, and user feedback.",[56,27],"SpO2 (Peripheral Oxygen Saturation) Measurement Validation","NOT_YET_RECRUITING","2026-06-29",{"date":60,"type":32},"2026-07-01",{"date":62,"type":21},"2026-06-15",{"date":64,"type":21},"2027-12-31",{"name":66,"class":39},"GE Healthcare",1,{"id":69,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":25,"conditions":72,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":40},"100610099",{"count":20,"type":21},[24],[27],"2026-03-02",{"date":75,"type":32},"2026-03-04",{"date":34,"type":32},{"date":78,"type":21},"2026-06-05",{"name":38,"class":39},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":15,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":105,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":67},"100624078","the-effect-of-surgical-mask-and-n95-mask-use-on-surgical-smoke-in-operating-room-nurses-100624078","NCT07404956","THE EFFECT OF SURGICAL MASK AND N95 MASK USE ON SURGICAL SMOKE IN OPERATING ROOM NURSES","COMPARISON OF THE EFFECTS OF SURGICAL MASK AND N95 MASK USE ON PHYSICAL SYMPTOMS OF SURGICAL SMOKE IN OPERATING ROOM","Inclusion Criteria:\n\n* Willingness to participate in the study\n* Aged 18 years or older\n* Working as a sterile operating room nurse at least 4 hours per day, 5 days per week\n* Compliance with the protocol requiring continuous use of both surgical mask and N95 mask for at least 4 hours per day\n* Ability to communicate verbally and provide informed consent\n\nExclusion Criteria:\n\n* Diagnosed psychiatric disorders\n* Presence of chronic respiratory, musculoskeletal, or neurological diseases\n* Presence of chronic dermatological conditions or allergies affecting the facial or respiratory area\n* Speech or communication impairments\n* Pregnancy\n* Holding a supervisory role (e.g., charge nurse) or non-sterile nursing role\n* Planned unit change or rotation during the study period","18 Years",{"count":89,"type":21},38,[24],"This study was conducted to compare the effect of surgical mask and N95 mask use on physical symptoms due to surgical smoke in operating theatre nurses. The study, which was conducted in a single-group prospective quasi-experimental design, was completed with 38 nurses in the operating theatre unit of a state hospital in the Western Black Sea Region. Data were collected for four weeks using the Descriptive Information Form, Numerical Rating Scale and Symptom Follow-up Form. According to the findings, muscle weakness, myalgia in the upper extremities and muscle cramps were statistically significantly less in nurses using N95 masks. Respiratory parameters, watery eyes and redness were significantly lower in nurses using surgical masks. As a result, it was determined that the type of mask was effective on the incidence of physical symptoms related to surgical smoke.",[93,94,95,96,97,98,99,100,101,27,102,103,104],"Surgical Smoke Exposure","Occupational Exposure to Surgical Smoke","Headache","Dizziness","Nause and Vomiting","Fatigue Symptom","Eye Allergies","Abdominal Pain (AP)","Heart Rate Determination","Muscle Weakness | Patient","Muscle Aches","Dispnea",[106,107,108,109],"Surgical Smoke","Masks","Operating Room Nurses","Occupational Exposure","2026-02-09",{"date":112,"type":32},"2026-02-12",{"date":114,"type":32},"2024-09-15",{"date":116,"type":21},"2026-02-28",{"name":118,"class":119},"Bartın Unıversity","OTHER",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":129,"phases":4,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":5},"100544685","project-mountain---comparing-spo2-and-sao2-for-accuracy-100544685","NCT06372106","Project Mountain - Comparing SpO2 and SaO2 for Accuracy","Philips FAST picoSAT Convenience Sampling for Clinical Performance in Neonate, Infant, and Pediatric Patients","Inclusion Criteria:\n\n* Subject aged 18 years or older or parent\u002Flegal guardian of subject aged less than 18 years, willing and able to understand and provide written informed consent\u002Fassent.\n* Weight and\u002For age within intended use of at least one SpO2 sensor under test at time of enrollment.\n* Willing and able to wear study devices in addition to SoC devices and during SoC procedures.\n* In-patient within a neonatal or pediatric intensive care unit (e.g. NICU, PICU, PCICU).\n* Has arterial access and ability to have arterial blood samples drawn as part of their SoC and analyzed by CO-Oximetry.\n\nExclusion Criteria:\n\n* Known pregnancy or lactating females (self-reported)\n* Injury, wounds, physical malformation, hyperkeratosis, or compromised\u002Fnon-intact skin at sensor application site (i.e. fingers, toes, hands, feet, ears, nasal ala). Note: Certain malformations may be allowed if determined it would not affect application of sensor with the pulse oximetry system.\n* Self-reported severe contact allergies to standard adhesives or other materials found in pulse oximetry sensors. Note: Subject may be considered eligible if subject can wear non-adhesive sensor.\n* Unwillingness or inability to remove nail polish or artificial nails from sensor application site.\n* Nail fungus on sensor application site.\n* Wearing and unable to remove jewelry from sensor application site.\n* Dye injection within 48 hours of enrollment.\n* Known dysfunctional hemoglobin levels (COHb \\>3%, MetHb \\>2%, and ctHb \\\u003C10g\u002Fdl)\n* Undergoing phototherapy for neonatal hyperbilirubinemia during arterial blood sampling",{"count":128,"type":21},560,"OBSERVATIONAL","The main goal of this study is to look at the performance of the neonatal, infant, and pediatric Philips SpO2 sensors with the Philips FAST Pulse Oximetry technology. Oxygen saturation measurements (SpO2) will be obtained via pulse oximetry and invasive arterial oxygen measurements (SaO2) will be obtained via arterial blood samples as part of your clinical care and assessed by co-oximetry. The study will aim to enroll a diverse population to help us understand the impact of skin pigmentation.",[27,132,133,134],"Nasal Alar Collapse, Bilateral","Oxygen","Measurement","2025-04-01",{"date":137,"type":32},"2025-04-02",{"date":139,"type":32},"2024-04-04",{"date":141,"type":21},"2025-12",{"name":143,"class":39},"Philips Clinical & Medical Affairs Global"]